Back to today’s briefing

Story perspectives

Sen. Ben Sasse lives after experimental drug cuts tumor 76%

4/29/2026

47 8 Full Breakdown

Summary

Story summary

Ben Sasse, U.S. Senator from Nebraska, told “60 Minutes” on April 28, 2026 he is alive while receiving daraxonrasib.
He was diagnosed with stage 4 pancreatic cancer in December 2025 and given three to four months to live.
In the Revolution Medicines phase 3 trial, daraxonrasib yielded a 13-month survival while Sasse’s tumor volume fell 76 percent over four months.

1 of 1

Story summary

Ben Sasse, U.S. Senator from Nebraska, told “60 Minutes” on April 28, 2026 he is alive while receiving daraxonrasib.
He was diagnosed with stage 4 pancreatic cancer in December 2025 and given three to four months to live.
In the Revolution Medicines phase 3 trial, daraxonrasib yielded a 13-month survival while Sasse’s tumor volume fell 76 percent over four months.